GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » ROE % Adjusted to Book Value

ANVS (Annovis Bio) ROE % Adjusted to Book Value : -37.51% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Annovis Bio ROE % Adjusted to Book Value?

Annovis Bio's ROE % for the quarter that ended in Dec. 2024 was -286.59%. Annovis Bio's PB Ratio for the quarter that ended in Dec. 2024 was 7.64. Annovis Bio's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -37.51%.

Annovis Bio ROE % Adjusted to Book Value Historical Data

The historical data trend for Annovis Bio's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annovis Bio ROE % Adjusted to Book Value Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - -17.40 -17.98 - -413.43

Annovis Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -125.61 -37.51

Competitive Comparison of Annovis Bio's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Annovis Bio's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annovis Bio's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annovis Bio's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Annovis Bio's ROE % Adjusted to Book Value falls into.


;
;

Annovis Bio ROE % Adjusted to Book Value Calculation

Annovis Bio's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-3,158.64% / 7.64
=-413.43%

Annovis Bio's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-286.59% / 7.64
=-37.51%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Annovis Bio's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Annovis Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annovis Bio Inc (NYSE:ANVS) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
FBLG ATRA GBIO KALA ABP VICP LSB VYNE INKT CELU VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
07X:Germany
Address
101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Website
https://www.annovisbio.com
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
Executives
Henry Iii Hagopian officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Mark K. White director 227 7TH AVENUE NE, ST. PETERSBURG FL 33701
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552
Maria-luisa Maccecchini director, officer: President and CEO 1223 FOXGLOVE LANE, WEST CHESTER PA 19380
Reid Mccarthy director 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jeffrey Brian Mcgroarty officer: Chief Financial Officer 360 HILLTOP RD, PAOLI PA 19301
Whelan, Jr. Robert M. director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Michael B Hoffman director 1 GREENWICH OFFICE PARK, GREENWICH CT 06831